Real-world effectiveness of a single conventional disease-modifying anti-rheumatic drug (cDMARD) plus an anti-TNF agent versus multiple cDMARDs in rheumatoid arthritis: a prospective observational study-Reference-Cited by-同舟云学术

Real-world effectiveness of a single conventional disease-modifying anti-rheumatic drug (cDMARD) plus an anti-TNF agent versus multiple cDMARDs in rheumatoid arthritis: a prospective observational study

Published:2024-01-29 Issue:2 Volume:31 Page:86-96
ISSN:2093-940X
Container-title:Journal of Rheumatic Diseases
language:en
Short-container-title:J Rheum Dis

Author:

So Min Wook¹^ORCID,Kim Sang-Hyon²^ORCID,Kim Dong Wook³^ORCID,Sung Yoon-Kyoung⁴^ORCID,Choe Jung-Yoon⁵^ORCID,Lee Sang-Il⁶^ORCID,Hur Jin-Wuk⁷^ORCID,Lee Hye-Soon⁸^ORCID,Lee Sang-Heon⁹^ORCID,Kim Jin Ran¹⁰^ORCID

Affiliation:

1. Division of Rheumatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea

2. Division of Rheumatology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea

3. Division of Rheumatology, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea

4. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea

5. Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea

6. Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine and Hospital, Jinju, Korea

7. Department of Internal Medicine, Eulji University College of Medicine, Seoul, Korea

8. Division of Rheumatology, Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea

9. Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea

10. Medical Department, MSL, Eisai Korea Inc., Seoul, Korea

Funder

Eisai Korea

Publisher

Korean College of Rheumatology

Link

https://pdf.medrang.co.kr/JRD/2024/031/JRD031-02-86.pdf

Reference26 articles.

1. Calabresi E, Petrelli F, Bonifacio AF, Puxeddu I, Alunno A. One year in review 2018: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 2018;36:175-84.

2. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization

3. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

4. Correction:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

5. Xeljanz (tofacitinib): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors [Internet]. Amsterdam: European Medicines Agency, 2021 Jul 6 [cited 2023 Jul 5]. Available from: https://www.ema.europa.eu/en/medicines/dhpc/xeljanz-tofacitinib-increased-risk-major-adverse-cardiovascular-events-malignancies-use-tofacitinib.